BIOMAT Database Logo BIOMAT Database Logo

Bone marrow granulomas in acute myeloid leukaemia following interleukin 2 and lymphokine-activated killer cells. 1992

D V O'Brien, and A P Boon, and B J Boughton
Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.

Granulomas are thought to represent an immune reaction to antigenic stimulation. Bone marrow granulomas are uncommon, but in the following case report we show their transient appearance after interleukin 2 (IL-2) and autologous lymphokine-activated killer cell therapy. This is a previously unreported association, and may implicate IL-2 in the pathogenesis of granulomas.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D001855 Bone Marrow Diseases Diseases involving the BONE MARROW. Bone Marrow Disease,Disease, Bone Marrow,Diseases, Bone Marrow,Marrow Disease, Bone,Marrow Diseases, Bone
D006099 Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents. Granulomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015479 Leukemia, Myelomonocytic, Acute A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin. Leukemia, Myeloid, Acute, M4,Leukemia, Myeloid, Naegeli-Type,Myeloid Leukemia, Acute, M4,Myeloid Leukemia, Naegeli-Type,Myelomonocytic Leukemia, Acute,Acute Myelomonocytic Leukemia,Acute Myelomonocytic Leukemias,Leukemia, Acute Myelomonocytic,Leukemia, Naegeli-Type Myeloid,Leukemias, Acute Myelomonocytic,Myeloid Leukemia, Naegeli Type,Myelomonocytic Leukemias, Acute,Naegeli-Type Myeloid Leukemia
D015979 Killer Cells, Lymphokine-Activated Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients. LAK Cells,Lymphokine-Activated Killer Cells,Cell, LAK,Cell, Lymphokine-Activated Killer,Cells, LAK,Cells, Lymphokine-Activated Killer,Killer Cell, Lymphokine-Activated,Killer Cells, Lymphokine Activated,LAK Cell,Lymphokine Activated Killer Cells,Lymphokine-Activated Killer Cell

Related Publications

D V O'Brien, and A P Boon, and B J Boughton
Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation.
January 1991, British journal of haematology,
D V O'Brien, and A P Boon, and B J Boughton
Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
February 1989, Cellular immunology,
D V O'Brien, and A P Boon, and B J Boughton
Interleukin-2 and lymphokine activated killer cells: promises and cautions.
January 1989, Annals of clinical and laboratory science,
D V O'Brien, and A P Boon, and B J Boughton
Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.
August 1993, Bone marrow transplantation,
D V O'Brien, and A P Boon, and B J Boughton
Treatment of cancer with lymphokine-activated killer cells and interleukin-2.
October 1987, The New England journal of medicine,
D V O'Brien, and A P Boon, and B J Boughton
Therapeutic uses of interleukin-2 and lymphokine-activated killer (LAK) cells.
June 1989, Blood reviews,
D V O'Brien, and A P Boon, and B J Boughton
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
June 1988, The New England journal of medicine,
D V O'Brien, and A P Boon, and B J Boughton
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
January 1988, Pathology and immunopathology research,
D V O'Brien, and A P Boon, and B J Boughton
[Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells].
February 1988, Schweizerische medizinische Wochenschrift,
D V O'Brien, and A P Boon, and B J Boughton
Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.
July 1995, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!